Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA – Get Free Report) CEO Sanj Patel sold 220,170 shares of the company’s stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $93.27, for a total transaction of $20,535,255.90. Following the completion of the sale, the chief executive officer owned 780,037 shares of the company’s stock, valued at approximately $72,754,050.99. This represents a 22.01% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Kiniksa Pharmaceuticals International Trading Up 2.7%
Shares of Kiniksa Pharmaceuticals International stock opened at $93.29 on Wednesday. The stock’s fifty day simple moving average is $79.67 and its 200 day simple moving average is $60.56. The company has a market capitalization of $7.28 billion, a PE ratio of 71.76 and a beta of 0.07. Kiniksa Pharmaceuticals International, plc has a 12 month low of $37.02 and a 12 month high of $98.48.
Kiniksa Pharmaceuticals International (NASDAQ:KNSA – Get Free Report) last posted its earnings results on Tuesday, October 27th. The company reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.19. The firm had revenue of $285.97 million during the quarter, compared to analysts’ expectations of $260.66 million. Kiniksa Pharmaceuticals International had a return on equity of 17.27% and a net margin of 11.58%. Analysts predict that Kiniksa Pharmaceuticals International, plc will post 1.30 EPS for the current fiscal year.
Key Kiniksa Pharmaceuticals International News
Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:
- Negative Sentiment: Across October 30 and November 2, CAO Michael Megna, COO Ross Moat, CFO Mark Ragosa and insider John Paolini reported sales totaling about 272,600 shares, worth approximately $25.4 million. The selling could weigh on sentiment or temper the stock’s recent momentum. However, each transaction was made under a pre-arranged Rule 10b5-1 plan, so it is not necessarily a response to new company developments. Megna SEC filing Moat SEC filing Paolini SEC filing Ragosa SEC filing
Analysts Set New Price Targets
A number of research firms recently issued reports on KNSA. Zacks Research cut Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 30th. Wedbush lifted their price target on shares of Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the company an “outperform” rating in a research note on Wednesday, October 28th. Wells Fargo & Company upped their price target on shares of Kiniksa Pharmaceuticals International from $87.00 to $110.00 and gave the company an “overweight” rating in a report on Wednesday, October 28th. JPMorgan Chase & Co. upped their price target on shares of Kiniksa Pharmaceuticals International from $107.00 to $122.00 and gave the company an “overweight” rating in a report on Friday, October 30th. Finally, The Goldman Sachs Group increased their price objective on shares of Kiniksa Pharmaceuticals International from $90.00 to $101.00 and gave the stock a “buy” rating in a research report on Wednesday, October 28th. Seven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $100.57.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of KNSA. Rubric Capital Management LP boosted its stake in shares of Kiniksa Pharmaceuticals International by 12.7% during the 1st quarter. Rubric Capital Management LP now owns 3,750,000 shares of the company’s stock worth $180,562,000 after buying an additional 421,347 shares during the last quarter. Pictet Asset Management Holding SA grew its holdings in shares of Kiniksa Pharmaceuticals International by 41.3% in the 3rd quarter. Pictet Asset Management Holding SA now owns 860,228 shares of the company’s stock valued at $64,182,000 after acquiring an additional 251,578 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Kiniksa Pharmaceuticals International by 18.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 811,922 shares of the company’s stock valued at $39,086,000 after acquiring an additional 128,417 shares in the last quarter. Spruce Street Capital LP increased its position in shares of Kiniksa Pharmaceuticals International by 75.0% in the first quarter. Spruce Street Capital LP now owns 761,063 shares of the company’s stock valued at $36,645,000 after acquiring an additional 326,081 shares during the last quarter. Finally, Bank of America Corp DE increased its position in shares of Kiniksa Pharmaceuticals International by 220.9% in the first quarter. Bank of America Corp DE now owns 735,940 shares of the company’s stock valued at $35,436,000 after acquiring an additional 506,576 shares during the last quarter. 53.95% of the stock is owned by institutional investors and hedge funds.
Kiniksa Pharmaceuticals International Company Profile
Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.
Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.
The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.
Read More
- Five stocks we like better than Kiniksa Pharmaceuticals International
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
- Palantir’s $2.3 Billion Quarter Puts Its Premium Valuation to the Test
Receive News & Ratings for Kiniksa Pharmaceuticals International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals International and related companies with MarketBeat.com's FREE daily email newsletter.
